NCT00456300View on ClinicalTrials.gov

Role of Exenatide in Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Type 1 Diabetes
Interventions
DRUG

Exenatide

In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.

DRUG

Insulin

Each subject received a baseline study with insulin alone

Trial Locations (1)

77030

Texas Children's Hospital/ Baylor College of Medicine, Houston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Montefiore Medical Center

OTHER

NCT00456300 - Role of Exenatide in Type 1 Diabetes | Biotech Hunter | Biotech Hunter